Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4.

Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 01/2003; 100(2):680-4. DOI: 10.1073/pnas.242735399
Source: PubMed

ABSTRACT Mutations in the serine-threonine kinases WNK1 and WNK4 [with no lysine (K) at a key catalytic residue] cause pseudohypoaldosteronism type II (PHAII), a Mendelian disease featuring hypertension, hyperkalemia, hyperchloremia, and metabolic acidosis. Both kinases are expressed in the distal nephron, although the regulators and targets of WNK signaling cascades are unknown. The Cl(-) dependence of PHAII phenotypes, their sensitivity to thiazide diuretics, and the observation that they constitute a "mirror image" of the phenotypes resulting from loss of function mutations in the thiazide-sensitive Na-Cl cotransporter (NCCT) suggest that PHAII may result from increased NCCT activity due to altered WNK signaling. To address this possibility, we measured NCCT-mediated Na(+) influx and membrane expression in the presence of wild-type and mutant WNK4 by heterologous expression in Xenopus oocytes. Wild-type WNK4 inhibits NCCT-mediated Na-influx by reducing membrane expression of the cotransporter ((22)Na-influx reduced 50%, P < 1 x 10(-9), surface expression reduced 75%, P < 1 x 10(-14) in the presence of WNK4). This inhibition depends on WNK4 kinase activity, because missense mutations that abrogate kinase function prevent this effect. PHAII-causing missense mutations, which are remote from the kinase domain, also prevent inhibition of NCCT activity, providing insight into the pathophysiology of the disorder. The specificity of this effect is indicated by the finding that WNK4 and the carboxyl terminus of NCCT coimmunoprecipitate when expressed in HEK 293T cells. Together, these findings demonstrate that WNK4 negatively regulates surface expression of NCCT and implicate loss of this regulation in the molecular pathogenesis of an inherited form of hypertension.


Available from: Maria D Lalioti, Sep 24, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin II increases NCC activity both acutely and chronically. Angiotensin II (ANGII) has been implicated as a switch which turns WNK4 from an inhibitor of NCC into an activator of NCC, and ANG II's effect on NCC appears to require WNK4. Chronically, ANGII stimulation of NCC results in an increase in total and phosphorylated NCC, but the role of NCC phosphorylation in acute ANGII actions is unclear. Here, using a mammalian cell model with robust native NCC activity, we corroborate the role that ANGII plays in WNK4 regulation and clarify the role of SPAK-induced NCC phosphorylation in ANGII action. ANGII was noted to have a biphasic effect on NCC, with a peak increases in NCC activity in the physiologic range of 10-11M ANGII. This effect was apparent as early as 15 minutes and remained sustained through 120 minutes. These changes correlated with significant increases in NCC surface protein expression. Knockdown of WNK4 expression sharply attenuated the effect of ANGII. SPAK knockdown did not affect ANGII action at early time points (15 and 30 minutes), but did attenuate the response at 60 minutes. Correspondingly, NCC phosphorylation did not increase at 15 or 30 minutes, but increased significantly at 60 minutes. We therefore conclude that within minutes of an increase in ANGII, NCC is rapidly trafficked to the cell surface in a phosphorylation-independent but WNK4-dependent manner. Then, after sixty minutes, ANGII induces SPAK-dependent phosphorylation of NCC. Copyright © 2014, American Journal of Physiology - Renal Physiology.
    American journal of physiology. Renal physiology 01/2015; DOI:10.1152/ajprenal.00465.2014 · 3.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypertension contributes to the global burden of cardiovascular disease. Increased dietary K(+) reduces blood pressure; however, the mechanism has been obscure. Human genetic studies have suggested that the mechanism is an obligatory inverse relationship between renal salt reabsorption and K(+) secretion. Mutations in the kinases with-no-lysine 4 (WNK4) or WNK1, or in either Cullin 3 (CUL3) or Kelch-like 3 (KLHL3)-components of an E3 ubiquitin ligase complex that targets WNKs for degradation-cause constitutively increased renal salt reabsorption and impaired K(+) secretion, resulting in hypertension and hyperkalemia. The normal mechanisms that regulate the activity of this ubiquitin ligase and levels of WNKs have been unknown. We posited that missense mutations in KLHL3 that impair binding of WNK4 might represent a phenocopy of the normal physiologic response to volume depletion in which salt reabsorption is maximized. We show that KLHL3 is phosphorylated at serine 433 in the Kelch domain (a site frequently mutated in hypertension with hyperkalemia) by protein kinase C in cultured cells and that this phosphorylation prevents WNK4 binding and degradation. This phosphorylation can be induced by angiotensin II (AII) signaling. Consistent with these in vitro observations, AII administration to mice, even in the absence of volume depletion, induces renal KLHL3(S433) phosphorylation and increased levels of both WNK4 and the NaCl cotransporter. Thus, AII, which is selectively induced in volume depletion, provides the signal that prevents CUL3/KLHL3-mediated degradation of WNK4, directing the kidney to maximize renal salt reabsorption while inhibiting K(+) secretion in the setting of volume depletion.
    Proceedings of the National Academy of Sciences 10/2014; 111(43). DOI:10.1073/pnas.1418342111 · 9.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although salt is a major environmental factor in the development of hypertension, the degree of salt sensitivity varies widely among individuals. The mechanisms responsible for this variation remain to be elucidated. Recent studies revealed the involvement of two important signaling pathways in renal tubules that play key roles in electrolyte balance and the maintenance of normal blood pressure: the β2 adrenergic stimulant-GR-WNK4-NCC pathway, which is active in distal convoluted tubules 1 (DCT1); and the Rac1-MR pathway, which is active in distal convoluted tubules 2 (DCT2), connecting tubules (CNT), and collecting ducts (CD). β2 stimulation due to increased renal sympathetic activity in obesity- and salt-induced hypertension suppresses HDAC8 activity via cAMP/PKA signaling, increasing the accessibility of the glucocorticoid receptor (GR) to the negative GR response element (GRE) in the WNK4 promoter. This results in the suppression of WNK4 transcription, followed by the activation of Na+-Cl- cotransporter (NCC) in DCT and elevated sodium retention and blood pressure upon salt loading. Rac1 activates mineralocorticoid receptors (MR), even in the absence of ligand binding, with this activity increased in the presence of ligand. In salt-sensitive animals, Rac1 activation due to salt loading activates MR in DCT2, CNT, and CD. Thus, GR and MR are independently involved in two pathways responsible for renal sodium handling and salt-sensitive hypertension. These findings suggest novel therapeutic targets and may lead to the development of diagnostic tools to determine salt sensitivity in hypertensive patients. Keywords: salt-sensitive hypertension, mineralocorticoid receptor, glucocorticoid receptor, Rac1, sympathetic nervous system. Copyright © 2013, American Journal of Physiology - Renal Physiology.
    American journal of physiology. Renal physiology 12/2014; DOI:10.1152/ajprenal.00477.2013 · 3.30 Impact Factor